Context: Combination therapies provide a potential solution to address the tumor
heterogeneity and drug resistance issues by taking advantage of distinct mechanisms of …

Abstract Context: Nanoparticles (NPs) have been widely used as carriers to deliver siRNA
and chemotherapeutic agents. Bcl-2 siRNA has been widely used to induce cancer cell …

Gefitinib (GEF) is utilized in clinical settings for the treatment of metastatic lung cancer.
However, premature drug release from nanoparticles in vivo increases the exposure of …

The clinical applications of natural anticancer drugs are being restricted by poor water
solubility, fast clearance in the circulation, lack of targeting to tumor cells, and poor tissue …

Introduction This study aims to develop a novel co-delivery gefitinib and quercetin system
loaded with PLGA-PEG nanoparticles and evaluate their antitumor activity in vitro and in …

Etoposide (ETP), as a potential treatment for lung cancer, has limited application due to its
poor solubility, and systemic side effects. In the current study, we propose inhalable …

Localized pulmonary delivery of anticancer agents to lungs has proven to be pioneering
approach for lung cancer therapy. Hybrid lipid nanocore-protein shell nanoparticles …

Purpose The present study aimed to develop gefitinib-loaded solid lipid nanoparticles (GEF-
SLN), and GEF-loaded PEGylated SLN (GEF-P-SLN) for targeting metastatic lung cancer …

There is an urgent need for new therapeutics for the treatment of aggressive and metastatic
refractory human non-small–cell lung cancer (NSCLC). Antiangiogenesis therapy and …

Lung cancer is an uncontrolled and abnormal mass of growing cells with the highest
mortality rate in the world. Progressive lung cancer shows a robust resistance to cancer …